Next generation protein production on cellular quality-control process

治疗性抗体是医药工业发展的主力。在日本，超过四分之一的生物药品是使用CHO细胞系生产的。最近有报道称，CHO细胞系可产生超过10 g/L的抗体。在本项目中，我们重点研究CHO细胞蛋白分泌过程的细胞质量控制系统。在质量控制机制的基础上，构建了改良蛋白生产体系。

Therapeutic antibody is workhorse for the development of pharmaceutical industries. In Japan, more than quarter of biopharmaceuticals was produced using CHO cell line. Recently, over 10 g/L antibody production was reported using CHO cell line. In this project, we focused on the cellular quality-control system for protein secretion process in CHO cell. On the basis of quality-control mechanism, we constructed the improved protein production system.